Group 1 - Fuda Alloy's controlling shareholder Wang Dawu plans to reduce his stake by up to 3% of the company's total shares, amounting to a maximum of 406.34 million shares, due to personal funding needs [1] - ST Songfa's subsidiary signed contracts for the construction of 17 vessels, with a total contract value between 1.6 billion to 1.8 billion USD [2] - Pairui Co. signed a technical cooperation agreement with a university to develop large-capacity power semiconductor devices and related power electronic modules, effective for three years [3] Group 2 - Shuangliang Energy indirectly participates in commercial aerospace projects, supplying heat exchangers for SpaceX's fuel production system, with orders totaling approximately 1.39 million CNY [4] - Hangya Technology plans to issue convertible bonds to raise up to 600 million CNY for various projects, including an intelligent manufacturing base in Malaysia [5] - Yuhua Development is publicly selling assets with a base price of 251 million CNY for residential properties [6] Group 3 - Penghui Energy plans to invest 2.1 billion CNY in a new battery production project in Zhengyang County, Henan Province, focusing on high-performance battery products [7] - Haige Communication's shareholder Yang Haizhou intends to reduce his stake by up to 0.1624% of the company's total shares [8] - Yaoshi Technology's controlling shareholder pledged 5.13% of shares to repay loans, with a pledge period from February 10, 2026, to February 2, 2027 [9][10] Group 4 - Hanyu Pharmaceutical received FDA approval for its drug Acetate Glatiramer Injection, used for treating relapsing multiple sclerosis [11] - Baiyao Tai's GoliMab Injection received EMA approval for various indications, including rheumatoid arthritis and ulcerative colitis [12] - Jiangxi Tungsten Equipment plans to issue A-shares to raise up to 1.882 billion CNY for acquisitions [13] Group 5 - Hesong New Materials expects to recognize asset impairment provisions between 23.6 million to 28.5 million CNY for 2025 [14] - ST Meichen's subsidiary is involved in two major lawsuits with a total amount of approximately 31.9 million CNY [15] - China Coal Energy reported a 7.3% year-on-year decline in coal sales for January 2026, with total sales of 20.05 million tons [16] Group 6 - Yida Co. plans to adjust its epoxy propylene derivative project, reducing the total investment from 845 million CNY to 642 million CNY [17] - Fosun Pharma's subsidiary received approval for a clinical trial of HLX15-SC for multiple myeloma treatment [18][19] - Yinfeng Communication's board members and executives have terminated their share reduction plan [20] Group 7 - Huazhong High-tech has waived its preferential purchase rights for a fund, extending the investment period from three to four years [21] - Warner Pharmaceuticals plans to participate in a national drug procurement program, with expected sales of 176 million CNY [22] - Changling Hydraulic announced a tender offer to acquire 12% of its shares at a price of 35.82 CNY per share [23] Group 8 - ST Chuan Zhi's stock may face delisting due to financial data falling below regulatory thresholds [24] - Tian Pharmaceutical and its subsidiaries are participating in a national drug procurement program, with expected sales of 323 million CNY [25] - China Metallurgical Group signed new contracts worth 73.65 billion CNY in January 2026 [26] Group 9 - Torus plans to invest 21.2 million CNY in a venture capital fund focused on artificial intelligence [27] - Shangwei Co. received a government subsidy of 1.764 million CNY, representing 10.79% of its net profit for 2024 [28] - Hanghua Co. reported a 21.97% decline in net profit for 2025, with total revenue of 1.249 billion CNY [29] Group 10 - Huaxia Bank reported a 1.72% decline in net profit for 2025, with total revenue of 91.914 billion CNY [30] - Guotou Fengle plans to transfer 51% of its stake in Hubei Fengle Ecological Fertilizer to optimize management [31] - Huaru Technology is co-investing in a fund with a total commitment of 20 million CNY [32] Group 11 - Jindike reported a loss of 173 million CNY for 2025, despite a 40.13% increase in revenue [33] - Zhenong Co. announced a 0.52% increase in shares held by a major shareholder [34] - Maike Audi plans to recognize asset impairment provisions of approximately 52.55 million CNY [35] Group 12 - Fuan Pharmaceutical's subsidiary is expected to be selected for a national drug procurement program, with projected sales of 680 million CNY [36] - Rundu Co. is participating in a national drug procurement program, with some products expected to be selected [37] - Changqing Co. has postponed its large-scale die-casting project to March 2027 due to customer requirements [38] Group 13 - Pan Asia Micro透 received a patent for a graphene-based automotive headlight defogging device [39] - Luan An Huan Neng reported a 17.1% increase in raw coal production for January 2026, totaling 5 million tons [40] - Guangji Pharmaceutical received a drug registration certificate for Mecobalamin Tablets [41] Group 14 - Ruifeng New Materials announced the resignation of its deputy general manager for personal reasons [42] - Zhiguang Electric's subsidiary signed a procurement contract for energy storage equipment worth 210.4 million CNY [43] - Youyan Powder Materials reported a 19.41% increase in net profit for 2025 [44] Group 15 - Jincheng reported a 22.2% increase in net profit for 2025, with total revenue of 253 million CNY [46]

Core Viewpoint - The company is actively progressing with the registration review of its innovative drug, Sodium Dehydroacetic Acid, and will disclose significant updates in accordance with regulatory requirements [1] Group 1: Drug Development and Approval - The registration review of Sodium Dehydroacetic Acid is proceeding in an orderly manner, with the specific progress dependent on the National Medical Products Administration (NMPA) [1] - The company maintains good communication with multiple clinical institutions involved in the research, establishing a solid professional foundation for future commercialization [1] - The company is open to collaborating with experienced and capable large teams for the promotion of this product [1] Group 2: Business Strategy and Operations - The company is actively expanding its overseas sales through localized strategies and is increasing efforts in Contract Manufacturing Organization (CMO) and Contract Development and Manufacturing Organization (CDMO) businesses [1] - The company is implementing cost reduction and efficiency enhancement measures to address industry competition and operational pressures [1] - The management is committed to protecting shareholder interests and ensuring sustainable operations, with plans to dynamically adjust development strategies based on industry trends and actual business conditions [1]

格隆汇2月12日丨润都股份(002923.SZ)公布，公司参加了国家组织集采药品协议期满品种接续采购办公 室(简称"接续采购办公室")组织的国家组织集采药品协议期满品种接续采购的投标工作(简称"本次接续 采购")，根据接续采购办公室于2026年02月10日发布的《国家组织集采药品协议期满品种接续采购拟中 选结果公示》，公司部分药品拟中选本次接续采购。 ...

证券代码：002923 证券简称：润都股份 公告编号：2026-013 珠海润都制药股份有限公司 关于公司参与国家组织集采药品协议期满品种接续 采购拟中选的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 | 序 | 品种名称 | 适应症 | | --- | --- | --- | | 号 | | | | | | 为了减少耐药细菌的发生，保持盐酸莫西沙星和其他抗菌 | | | | 药物的有效性，盐酸莫西沙星应该仅用于治疗已被证明或 | | | | 强烈怀疑由敏感细菌引起的感染。 | | | | 在取得培养和药敏信息的情况下，应根据结果选择继续使 | | | | 用或换用其他药物。在缺少这些数据的情况下，当地致病 | | | | 菌的流行病学和敏感谱可能有助于治疗药物的经验选择。 | | | | 治疗前应进行适当的培养和药敏试验，以分离和鉴定引起 | | | | 感染的微生物，并确定其对盐酸莫西沙星的敏感性。 | | | | 在获得培养结果之前可能已经选择盐酸莫西沙星进行治 | | | | 疗，一旦获得培养结果，应选择适当的治疗。 | | | | 盐酸莫西沙 ...

Core Viewpoint - The company is actively progressing with the registration review of its innovative drug, CXHS2400019, and is prepared for potential commercialization while addressing industry competition and operational pressures [1]. Group 1: Drug Approval and Commercialization - The registration review for the innovative drug, CXHS2400019, is currently in progress, with the specific timeline dependent on the National Medical Products Administration (NMPA) [1]. - The company maintains good communication with clinical institutions involved in the research, which lays a solid foundation for future commercialization efforts [1]. - The company is open to collaborating with experienced and capable teams for the promotion of the drug [1]. Group 2: Business Strategy and Financial Performance - The company is actively expanding its overseas sales and enhancing its Contract Manufacturing Organization (CMO) and Contract Development and Manufacturing Organization (CDMO) operations to reduce costs and improve efficiency [1]. - The company reported its first loss in 2025, indicating a challenging competitive environment in the pharmaceutical sector [1]. - The management is focused on maintaining shareholder interests and ensuring sustainable operations, with plans to dynamically adjust development strategies based on industry trends and actual business conditions [1].

| 权益类证券大宗交易(协议交易) | | | | | | | 团 下载 | | --- | --- | --- | --- | --- | --- | --- | --- | | 交易日期 | 证券代码 | 证券简称 | 成交价格 (元) | 成交量 (万股/万份) | 成交金额 (万元) | 买方营业部 | 卖方营业部 | | 2026-02-11 | 002923 | 润都股份 | 14.96 | 20.00 | 299.20 机构专用 | | 华西证券股份有限 | | | | | | | | | 公司佛山南海大道 | | | | | | | | | 证券营业部 | 2月11日，润都股份大宗交易成交20万股，成交额299.2万元，占当日总成交额的1.99%，成交价14.96 元，较市场收盘价16.38元折价8.67%。 ...

Group 1 - The core point of the article is that Rundu Co., Ltd. has received a drug registration certificate for Candesartan Cilexetil Tablets from the National Medical Products Administration [2] Group 2 - The announcement was made on February 9, indicating a significant regulatory milestone for the company [2] - The approval of the drug may open new market opportunities for Rundu Co., Ltd. in the pharmaceutical sector [2] - This development highlights the company's ongoing efforts to expand its product portfolio and enhance its competitive position in the industry [2]

证券日报网讯2月9日，润都股份（002923）在互动平台回答投资者提问时表示，截至2026年1月30日， 公司总户数为17769户。 ...

Group 1 - XianDao Intelligent has set the final price for its H-share public offering at HKD 45.8 per share, with expected listing on February 11, 2026 [1] - Jida Communication is a candidate for a project with China Mobile, with an estimated service fee of approximately CNY 51.04 million [2] - Bowei Alloy's controlling shareholder plans to increase holdings by CNY 100 million to 150 million from February 10 to August 9, 2026 [3] Group 2 - Xiamen Airport reported 16,368 aircraft takeoffs and landings in January 2026, a year-on-year decrease of 4.82%, with passenger throughput of 2.38 million, down 3.84% [4] - Yitong Century has won a bid for a project worth CNY 107 million, providing comprehensive maintenance services for China Tower [5] - Huayi Brothers' controlling shareholder's 70 million shares are subject to judicial auction, representing 42.89% of his holdings and 2.52% of the company's total shares [6] Group 3 - Lianhuan Pharmaceutical received approval for the sale of Tadalafil tablets (20mg) in Ghana [7] - Aonong Biological reported a pig sales volume of 166,600 in January 2026, a year-on-year increase of 35.36% [8] - Xiantan Co. achieved chicken product sales revenue of CNY 546 million in January 2026, a year-on-year increase of 54.9% [9] Group 4 - Zhengbang Technology reported a January sales revenue of CNY 816 million from pig sales, a year-on-year increase of 19.69% [10] - Qianjin Pharmaceutical's net profit for 2025 grew by 24.74% to CNY 288 million [11] - Xinhua Pharmaceutical received a drug registration certificate for glucosamine sulfate capsules [12] Group 5 - Yuandong Bio completed the first dosing of its EP-0210 monoclonal antibody in a Phase I clinical trial for inflammatory bowel disease [13] - Jiaokong Technology signed a contract for the Sydney Metro West Line signal system subcontracting project worth AUD 93.53 million [14] - Dangsheng Technology signed a strategic cooperation framework agreement with Huineng Technology in solid-state batteries and the new energy industry [15] Group 6 - Jinhui Co. plans to acquire 100% of Fusheng Mining for CNY 210 million [16] - Cangzhou Mingzhu announced Guangzhou Light Industry as its new controlling shareholder after a share transfer [17] - Dingxin Technology's vice president was fined CNY 120,000 for short-term trading [18][19] Group 7 - China Modern Pharmaceutical's subsidiary passed a GMP compliance inspection for its production line [20] - Chaosheng Electronics plans to increase capital by CNY 400 million in its subsidiary to enhance competitiveness [21] - Lonyu Mountain reported a 25.03% year-on-year increase in pig sales revenue in January 2026 [22] Group 8 - Sanbo Brain Science's chairman has been released from investigation, and the company is operating normally [23] - Hainan Mining is planning to acquire control of Luoyang Fengrui Fluorine Industry and will resume trading on February 10, 2026 [24] - Dongwei Technology's net profit for 2025 increased by 86.81% [25] Group 9 - Yuanjie Technology plans to invest CNY 1.251 billion in a semiconductor chip and device R&D production base [26] - Metro Design signed a contract for an energy management project with Guangzhou Metro Group worth CNY 924 million [27] - Zhongmin Energy intends to acquire 51% of Fujian Yongtai Mintou Pumped Storage Co. for CNY 864 million [28] Group 10 - Dianzhi Technology plans to repurchase shares worth CNY 100 million to 200 million [29] - China Baoan was not selected as a restructuring investor for the Singshan Group [30] - Zhiguang Electric's subsidiary signed a CNY 1.004 billion contract for energy storage systems [31] Group 11 - Zhifei Biological received approval for a clinical trial of its herpes zoster vaccine [32] - KQ Bio received a new veterinary drug registration certificate for a vaccine against porcine circovirus type 2 [33] - Huanxu Electronics reported a 4% year-on-year increase in consolidated revenue for January 2026 [34] Group 12 - Xiangjia Co. reported a 10.42% year-on-year increase in live poultry sales revenue in January 2026 [35] - Kemin Foods' subsidiary reported a 68.29% year-on-year increase in pig sales revenue in January 2026 [36] - Liyuan Technology signed a procurement contract worth CNY 54.98 million [37] Group 13 - Jiuqiang Bio received a medical device registration certificate for a fibrin degradation product detection kit [38] - Zhongguancun's subsidiary passed the consistency evaluation for Tramadol Hydrochloride tablets [39] - Rundou Co. received a drug registration certificate for Candesartan Etil [40]

| 交易日期 | 证券代码 | 证券简称 | 成交价格 (元) | 成交量 | 成交金额 (万元) | 买方营业部 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | (万股/万份) | | | | | 2026-02-09 | 002923 | 润都股份 | 14.76 | 13.60 | 200.74 机构专用 | | 华西证券股份有限 | | | | | | | | | 公司佛山南海大道 | | | | | | | | | 证券营业部 | 2月9日，润都股份大宗交易成交13.6万股，成交额200.74万元，占当日总成交额的0.87%，成交价14.76元，较市场收盘价 16.49元折价10.49%。 ...